Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

90 subjects with ischemic cardiomyopathy will be randomized to receive a single dose of 15
or 30 mg of JVS-100 or matching placebo. Subjects will be randomized 1:1:1 to receive either
placebo, 15 mg or 30 mg of JVS-100. Subjects will be monitored overnight for 18-24 hours
post dose and have scheduled visits at 3 days post-injection for safety evaluations. All
subjects will be scheduled for follow-up visits at approximately 30 days (1 month), 120 days
(4 months), and 360 days (12 months) to assess safety and cardiac function.

Inclusion Criteria:

- Willing and able to sign informed consent

- Greater than or equal to 18 years of age

- Subjects with 6 minute hall walk distance ≤ 400 m limited only by cardiac fitness

- Minnesota LWHF questionnaire score ≥20 points

- Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months

- Residual well-demarcated region of LV systolic dysfunction defined as at least 3
consecutive segments of abnormal wall motion by echocardiography read at the
echocardiography core laboratory

- LVEF ≤40% measured by echocardiography read at the echocardiography core laboratory

- Must meet wall thickness criteria

- Subject has an implanted, functional AICD

- Subjects with diabetes must have had an ophthalmologist exam within the last year
showing no active proliferative retinopathy

- Subject receiving stable optimal pharmacological therapy defined as:

- ACE inhibitor and/or ARB, and Beta-blocker for 90 days with stable dose for 30
days unless contraindicated

- Diuretic in subjects with evidence of fluid retention

- ASA unless contraindicated

- Statin unless contraindicated

- Aldosterone antagonist per physician discretion

Exclusion Criteria:

- Planned revascularization within 30 days following enrollment

- Estimated Glomerular Filtration Rate < 30 ml/min*

- Signs of acute heart failure within 24 hours of scheduled injection

- History of aortic valve regurgitation classified as "moderate" or severe

- Moderate/Severe aortic stenosis defined as AVA <1.5 cm2

Note: Patient should not be excluded if the patient's medical records document that within
the last 6 months the patient has either:

- no aortic stenosis

- mild aortic stenosis

- normal aortic valve

- normal aortic pressure gradient

- aortic pressure gradient < 20 mmHg

- Presence of an artificial aortic valve

- Subjects with aortic aneurysm >3.8 cm

- Mitral regurgitation defined as "severe" measured by echocardiography at the
clinical site.

- Patients with planned mitral valve repair or replacement surgery

- Any patient with a history of cancer will be excluded unless:

- The cancer was limited to curable non-melanoma skin malignancies and/or

- The cancer was removed by a successful tumor resection, with or without radiation or
chemotherapy treatment, 5 years or more prior to enrollment in this study without
recurrence

Subjects must have the following results on age appropriate cancer screenings:

- Subjects age 50 or older have had a Fecal occult blood test (FOBT) or fecal
immunochemical test (FIT) that was negative within the last year

- Women age 30 or older have had a PAP test that was negative within the last 3 years

- Women age 40 or older have had a mammogram that was negative within the last year

- Men above age 45 have had a Prostate-Specific Antigen (PSA) blood test and digital
rectal examination (DRE) that was negative within the last year

- At the request of the site principal investigator, any subject with a non-negative
result thought to be due to a non-cancer-related condition will be evaluated by the
medical monitor for enrollment

Exclusion Criteria (ctd):

- Subjects with persistent or chronic atrial fibrillation will be excluded unless:

- A stable, regular heart rate is maintained with a biventricular pacemaker

- A stable, regular heart rate is maintained with a univentricular pacemaker
pacing less than or equal to 40% of the time

- Subjects with Biventricular pacing device implant within the last 3 months OR
previously implanted Biventricular pacing device with programming planned to be
reoptimized following enrollment in this trial

- Previous solid organ transplant

- Subjects with greater than 40% univentricular RV Pacing

- Subjects with uncontrolled diabetes defined as HbA1c >9.0%

- Inability to complete 6 minute walk or treadmill exercise test

- Participation in an experimental clinical trial within 30 days prior to enrollment

- Any subject who has been enrolled in a gene or stem cell therapy cardiac trial
within the last year

- Life expectancy of less than 1 year

- Positive pregnancy test (serum βHCG) in women of childbearing potential and/or
unwillingness to use contraceptives or limit sexual activity as described in Section
8.2.1 below

- Unwillingness of men capable of fathering a child to agree to use barrier
contraception or limit sexual activity as described in Section 8.2.1 below

- Subjects who are breast feeding

- Subjects with a positive test results for hepatitis B/C and/or HIV

- Total Serum Bilirubin >4.0 mg/dl

- Aspartate aminotransferase (AST) > 120 IU/L

- Alanine aminotransferase (ALT) > 135 IU/L

- Alkaline phosphatase (ALP) >300 IU/L

- Clinically significant elevations in PT or PTT relative to laboratory norms

- Any subject with a known existing LV thrombus or has an LV thrombus detected during
the screening period of this study.

- Subjects with Rutherford class 5 or 6 critical limb ischemia

- Subject with severe chronic obstructive pulmonary disease (COPD)

- Any subject requiring home oxygen use

- Subjects with a history of Systemic Lupus Erythematosus (SLE) flare

- History of drug or alcohol abuse within the last year

- A subject will be excluded if he/she is unfit for the trial based on the discretion
of the site Principal Investigator